Table 4.
MiRNA Associations with Pulmonary Function Measures
| FEV1 | FVC | |||||||
|---|---|---|---|---|---|---|---|---|
| miRNA | Samples | Estimated β* | SE | P-value† | Samples | Estimated β* | SE | P-value† |
|
| ||||||||
| miR-1180 | 4539 | −15.1 | 5.8 | 9.5×10−3 | 4539 | −17.9 | 7.2 | 0.01 |
|
| ||||||||
| miR-181a-2-3p | 4530 | −1.1 | 6.1 | 0.86 | 4530 | −2.3 | 7.5 | 0.76 |
|
| ||||||||
| miR-423-5p | 4092 | −6.4 | 4.4 | 0.14 | 4092 | −8.7 | 5.4 | 0.11 |
|
| ||||||||
| miR-25-5p | 4492 | −2.6 | 4.2 | 0.53 | 4492 | −8.6 | 5.3 | 0.10 |
|
| ||||||||
| miR-1285-3p | 4299 | 4.7 | 4.6 | 0.30 | 4299 | 1.6 | 5.7 | 0.78 |
|
| ||||||||
| miR-342-5p | 1100 | −1.3 | 9.0 | 0.89 | 1100 | 5.4 | 11.1 | 0.63 |
|
| ||||||||
| FEV1/FVC | Airflow Obstruction | |||||||
| miRNA | Samples | Estimated β* | SE | P-value† | Samples | Estimated β* | SE | P-value† |
|
| ||||||||
| miR-1180 | 4539 | −2.8×10−4 | 8.0×10−4 | 0.72 | 4539 | 0.01 | 2.7×10−3 | 1.8×10−3 |
|
| ||||||||
| miR-181a-2-3p | 4530 | 7.2×10−6 | 8.3×10−4 | 0.99 | 4530 | 1.9×10−3 | 2.8×10−3 | 0.50 |
|
| ||||||||
| miR-423-5p | 4092 | 1.6×10−4 | 5.9×10−4 | 0.78 | 4092 | 4.2×10−3 | 2.0×10−3 | 0.03 |
|
| ||||||||
| miR-25-5p | 4492 | 8.3×10−4 | 5.7×10−4 | 0.15 | 4492 | −1.3×10−3 | 1.9×10−3 | 0.51 |
|
| ||||||||
| miR-1285-3p | 4299 | 5.9×10−4 | 6.3×10−4 | 0.35 | 4299 | 1.1×10−3 | 2.1×10−3 | 0.60 |
|
| ||||||||
| miR-342-5p | 1100 | −1.8×10−3 | 1.1×10−3 | 0.13 | 1100 | 0.01 | 4.1×10−3 | 0.10 |
*
Estimated β coefficients represent the mean differences in the stated pulmonary function measure per one standard deviation difference in miRNA CT value, where higher CT values reflect lower miRNA expression.
†
The p-value threshold for significance (p<1.4×10−3) was determined by the Bonferroni method [0.05/(6 smoking-associated miRNAs*6 clinical phenotypes tested)]. Marginally significant p-values are shown in bold.